Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Boston Scientific Corp., liquidity ratios (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).


Current Ratio
The current ratio exhibited fluctuations throughout the analyzed periods. Initially, it started at 1.39 at the end of the first quarter of 2019 and experienced a decline to a low of 0.97 by the end of 2019, indicating a reduction in liquidity during this period. Subsequently, a significant increase was observed in the first half of 2020, reaching 1.87 by June and September 2020, suggesting an improvement in short-term financial stability. From late 2020 through mid-2021, the ratio showed a gradual downward trend, declining to 1.48 by the end of 2021. The following quarters witnessed further decline to 1.18 in March 2022, followed by a moderate recovery through late 2022 and early 2023, stabilizing around 1.4 in March 2023. Overall, the current ratio indicates variable liquidity management, with notable strengthening in mid-2020 and a moderate but stable position in recent quarters.
Quick Ratio
The quick ratio trends displayed similar variability with some differences relative to the current ratio. Starting at 0.39 in the first quarter of 2019, it remained below 0.5 for most of 2019, indicating lower immediate liquidity excluding inventories. A marked increase occurred in mid-2020, peaking at 1.10 in September 2020, signaling improved ability to meet short-term liabilities with liquid assets. However, this peak was followed by a decline during late 2020 and throughout 2021, bottoming near 0.87 in December 2021. The ratio further declined in early 2022 to approximately 0.51, then experienced a gradual recovery toward 0.76 in December 2022 before settling at 0.65 in March 2023. These fluctuations imply adjustments in liquidity strategy, with the company briefly achieving strong quick liquidity but largely maintaining moderate levels.
Cash Ratio
The cash ratio, representing the most conservative liquidity measure, showed minimal initial values in early 2019, starting at 0.03 and remaining under 0.1 during that year. A significant surge appeared around mid-2020, reaching 0.61 in the third quarter, reflecting an increased cash or cash-equivalent position. This peak was followed by a decline throughout late 2020 and 2021, with the ratio falling back to around 0.45 by December 2021. In 2022, the ratio sharply decreased to levels below 0.1 in the first half of the year before recovering moderately to 0.24 by December 2022 and then retreating again to 0.14 in the first quarter of 2023. This pattern suggests the company temporarily boosted its most liquid assets in response to external conditions but later reduced cash holdings, perhaps reallocating resources or managing cash flow needs differently.

Current Ratio

Boston Scientific Corp., current ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several key trends in the liquidity position over the observed periods.

Current Assets
Current assets exhibit fluctuations throughout the timeline. Initially, there is a decline from the first quarter of 2019 through the end of the year, reaching a low point near the fourth quarter of 2019. From early 2020, current assets increase notably, peaking around the end of 2020. Following this peak, a general downtrend occurs until early 2022, after which the value stabilizes with minor increases towards the first quarter of 2023. Overall, current assets reflect a cyclical pattern with a significant recovery phase observed in 2020.
Current Liabilities
Current liabilities demonstrate a more variable pattern with less pronounced trends compared to current assets. Early in 2019, liabilities rise somewhat but then fall sharply midway through 2020, hitting the lowest point around the second quarter of 2020. After this decline, liabilities gradually increase again, reaching relatively high levels by the end of 2021. From 2022 onward, current liabilities reduce moderately but show a slight upward movement at the beginning of 2023. The data suggest active management of short-term obligations with some volatility.
Current Ratio
The current ratio, a key liquidity indicator, reflects these changes in assets and liabilities. Starting above 1.3 in early 2019, it decreases to below 1.0 by the end of 2019, indicating tighter liquidity conditions. Subsequently, a strong improvement occurs in 2020, with the ratio rising near 1.9, signaling enhanced liquidity and short-term financial health. However, after this peak, the ratio steadily declines from 2021 through much of 2022, though it remains above 1.0, indicating adequate liquidity. In the final quarters, there is a modest recovery with the ratio stabilizing around 1.4 to 1.5. This pattern suggests periods of both constrained and strengthened liquidity, with an overall capacity to meet current liabilities adequately.

In summary, the data reflect a dynamic liquidity landscape marked by an initial tightening through 2019, a robust recovery in 2020 with improved current assets and liquidity ratios, followed by moderate adjustments through 2021 and 2022. The current ratio's maintenance above unity throughout most periods indicates sustained ability to cover short-term liabilities despite the fluctuations in asset and liability levels.


Quick Ratio

Boston Scientific Corp., quick ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Trade accounts receivable, net
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


Trend in Total Quick Assets
Total quick assets exhibit notable fluctuations over the observed periods. Initially, they increased from 1760 million USD in March 2019 to a peak of 2073 million USD in September 2019, followed by a slight decline towards the end of 2019. A significant rise occurred in the first half of 2020, peaking at 3620 million USD in September 2020, before experiencing a moderate decline during the last quarter of 2020. The asset levels again increased up to June 2021, reaching 4350 million USD, the highest in the series, then dropped sharply by the first quarter of 2022, settling around 2191 million USD. Thereafter, total quick assets remained relatively stable with modest growth through 2022, ending at 2646 million USD in March 2023.
Trend in Current Liabilities
Current liabilities presented a generally unstable pattern with moderate swings throughout the quarters. Starting at 4479 million USD in March 2019, liabilities increased to a peak of 4866 million USD by December 2019. The first half of 2020 saw a notable reduction, dropping to 3108 million USD in June, but then liabilities rose again throughout the remainder of 2020 to 3681 million USD by year-end. In 2021, current liabilities fluctuated between 3393 million USD and 4274 million USD, maintaining elevated levels. From 2022 onward, liabilities trended downward, falling to 3549 million USD by September before rising slightly towards 4083 million USD in March 2023.
Analysis of Quick Ratio
The quick ratio, a measure of liquidity, varied substantially during the period. Initially low at around 0.39 in early 2019, it gradually increased, reaching above 1.0 in mid to late 2020, peaking at 1.10 in September 2020. This indicates stronger short-term financial health during that time. During 2021, the ratio remained at or slightly below 1.0, suggesting balanced liquidity. However, from early 2022, there's a clear decline in the quick ratio to a low of 0.51 by March 2022, reflecting a weakening liquidity position. A minor recovery occurred toward the end of 2022 and early 2023, with the ratio rising to 0.76 but still below 1.0, indicating some improvement yet remaining below optimal liquidity levels.
Overall Liquidity Assessment
The observed trends highlight periods of strong liquidity, particularly in 2020 and early 2021, followed by a marked deterioration in 2022. The fluctuations in total quick assets and current liabilities contributed to volatility in the quick ratio. The decreased quick ratio in 2022 signals increased risk in meeting short-term obligations through liquid assets. While there is a modest recovery in early 2023, liquidity remains below the levels seen during the peak periods, suggesting cautious monitoring of working capital and short-term financial management may be warranted.

Cash Ratio

Boston Scientific Corp., cash ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The analysis of the financial trends reveals several important insights regarding liquidity and short-term financial stability.

Total Cash Assets
The total cash assets demonstrated volatility over the observed period. From a relatively low base in early 2019, a marked increase occurred in mid-2020, peaking notably in June and September 2020. Subsequently, cash assets declined significantly throughout 2021 and early 2022, reaching their lowest points in March and June 2022. A moderate recovery is observed in the latter part of 2022 and early 2023, although cash levels remain well below the mid-2020 peak.
Current Liabilities
Current liabilities fluctuated within a moderate range without a clear long-term upward or downward trend. Starting near 4,479 million USD in early 2019, liabilities decreased slightly during mid-2020 but then rose again toward the end of 2020 and throughout 2021. A mild decreasing trend was noticeable through most of 2022, with liabilities increasing again slightly in early 2023, ending marginally above the initial figures from 2019.
Cash Ratio
The cash ratio, representing the company's immediate liquidity, closely mirrored the fluctuations in total cash assets relative to current liabilities. Initially low and stable near 0.03 to 0.07 during 2019, the ratio surged sharply in mid-2020, reaching peaks in the range of 0.55 to 0.66. This reflects strengthened liquidity during this period, likely due to raised cash reserves. However, a subsequent decline over 2021 and early 2022 brought the ratio back down to levels near 0.07 to 0.10, indicating diminished liquidity. A partial recovery in the cash ratio is evident again toward early 2023, though it remains well below the mid-2020 peak.

Overall, the company exhibited a significant enhancement in liquidity during the middle of 2020, supported by a substantial increase in cash assets and a resulting stronger cash ratio. This peak was not sustained, as both cash assets and liquidity ratios declined through 2021 and early 2022, before showing tentative improvements by early 2023. Current liabilities remained relatively stable, suggesting that liquidity changes were predominantly driven by fluctuations in cash holdings rather than shifts in short-term obligations.